OVARIAN GROWTH FACTORS
OVARIAN GROWTH FACTORS
批准号:
6625207
负责人:
JAMES M HAMMOND
金额:
$36.75万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-12-01 至 2004-05-31
关键词:
DNA footprinting beta galactosidase biological models biological signal transduction follicle stimulating hormone gene expression genetic promoter element genetic regulation genetically modified animals graafian follicles granulosa cell growth factor receptors hormone regulation /control mechanism hyperinsulinism insulinlike growth factor intermolecular interaction laboratory mouse model design /development ovary phosphorylation polycystic ovary syndrome polymerase chain reaction protein kinase reproductive development transcription factor transfection
中文摘要
在拟议的支持期内,我们将延长我们长期以来的
对卵巢胰岛素样生长因子(IGF)系统的兴趣
了解程度足以在活体内控制这个系统。此后,
所评估的概念和可能的一些化合物可用于
提高动物的生育力,并最终提高妇女的生育力。投射的关键
进展是了解IGF-I系统与激素的接口
和生长因子信号在早期卵泡发育和
生殖周期。划定了两个控制点:(1)
颗粒细胞胰岛素样生长因子-I生物合成的生理调控。在这一地区,
事实证明,我们的系统具有独特的信息量。在具体目标1中,我们将
继续这些研究,从分子的角度定义FSH和FSH的相互作用
其环状AMP依赖于IGF-I启动子的级联反应。展示的效果
该基因的其他刺激物将被追踪到其他启动子元件。
为了在体内测试这些调节原理,表达IGF-I启动子
转基因将在转基因小鼠身上进行测试。(2)在具体目标2中,研究
影响IGF-I基因的细胞机制将扩展到其他
卵巢细胞功能的各个方面。这一具体目标的目标是
了解胰岛素样生长因子与促卵泡激素的相互作用
颗粒细胞在不同时期的复制、存活和分化
卵泡的寿命。这些研究将制定一项详细的
调节这些效应的信号转导通路的图片。
《特定目标3》使用转基因方法来检验所得出的假设。
来自特定目标1和2的早期描述性研究和体外研究
通过体内转基因方法。控制和控制的目标
调查将包括IGF-I的局部合成和IGF-I的作用
通过其受体和磷酸化中的多个点介导
从这个感受器发出的级联。这些研究中的大多数都有临床
相关性,因为要检查的信号级联的抑制物是
变得广泛可用,因为足够数量的各种IGF
衍生品现在可以用在人类身上,作为可能的放大
排卵机制。然而,最直接的一系列实验
临床相关的是那些寻求使用条件转基因的人
建立多囊卵巢胰岛素抵抗模型的技术
综合症。如果成功,这种模式可能会打开批判性评估的大门,
了解和治疗方式。
英文摘要
In the proposed period of support, we will extend our longstanding
interest in the ovarian insulin-like growth factor (IGF) system to achieve a
level of understanding sufficient to control this system in vivo. Thereafter,
the concepts and possibly some of the compounds evaluated can be used to
improve fertility in animals and ultimately women. The key to the projected
advances is understanding the interface of the IGF-I system with the hormone
and growth factor signals during early follicle development and the
reproductive cycle. Two control points have been delineated: (1) The
physiological control of IGF-I biosynthesis in granulosa cells. In this area,
our systems have proven to be uniquely informative. In Specific Aim 1, we will
continue these studies to define in molecular terms the interaction of FSH and
its cyclic AMP-dependent cascade on the IGF-I promoter. The demonstrated effect
of other stimulators of this gene will be tracked to other promoter elements.
To test these regulatory principles in vivo, expression IGF-I promoter
transgenes will be tested in transgenic mice. (2) In Specific Aim 2, studies of
the cell machinery which impacts on the IGF-I gene will be expanded to other
aspects of ovarian cell function. The goal of this specific aim is to
understand the interaction of IGF with FSH which demonstrably enhances
granulosa cell replication, survival and differentiation at various times in
the lifespan of the ovarian follicle. These studies will develop a detailed
picture of the signal transduction pathways which mediate these effects.
Specific Aim 3 employs transgenic approaches to test the hypotheses derived
from earlier descriptive studies and in vitro studies in Specific Aims 1 and 2
through transgenic approaches in vivo. The targets for control and
investigation will include the local synthesis of IGF-I and IGF-I action
mediated through its receptor and multiple points in the phosphorylation
cascade which emanate from this receptor. Most of these studies have clinical
relevance because inhibitors for the signal cascades to be examined are
becoming widely available and because sufficient quantities of various IGF
derivatives are now available to use in humans as a possible amplifying
mechanism for ovulation. However, the series of experiments of most direct
clinical relevance are those which seek to use conditional transgenic
technology to build an insulin-resistant model of the polycystic ovarian
syndrome. If successful, this model could open the door to critical evaluation,
understanding, and treatment modalities.
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Characterization of insulin-like growth factor-binding proteins of porcine ovarian follicular fluid.
猪卵巢卵泡液胰岛素样生长因子结合蛋白的表征。
DOI:
10.1095/biolreprod44.2.315
发表时间:
1991
期刊:
Biology of reproduction
影响因子:
3.6
作者:
[Mondschein,JS, Etherton,TD, Hammond,JM]
通讯作者:
Hammond,JM
DOI:
10.1210/endo.139.12.6367
发表时间:
1998
期刊:
Endocrinology
影响因子:
4.8
作者:
[S. Wandji;T. Wood;Jennifer Crawford;S. Levison;J. Hammond]
通讯作者:
S. Wandji;T. Wood;Jennifer Crawford;S. Levison;J. Hammond
DOI:
10.1210/endo-127-5-2298
发表时间:
1990-11
期刊:
Endocrinology
影响因子:
4.8
作者:
[J. Mondschein;Sheila A. Smith;J. Hammond]
通讯作者:
J. Mondschein;Sheila A. Smith;J. Hammond
DOI:
10.2527/1995.7361776x
发表时间:
1995-06
期刊:
Journal of animal science
影响因子:
3.3
作者:
[A. Clutter;L. Spicer;M. Woltmann;R. Grimes;J. Hammond;D. S. Buchanan]
通讯作者:
A. Clutter;L. Spicer;M. Woltmann;R. Grimes;J. Hammond;D. S. Buchanan
DOI:
10.1152/ajpendo.1992.262.4.e497
发表时间:
1992-04
期刊:
The American journal of physiology
影响因子:
--
作者:
[R. Grimes;S. Samaras;J. Barber;S. Shimasaki;N. Ling;J. Hammond]
通讯作者:
R. Grimes;S. Samaras;J. Barber;S. Shimasaki;N. Ling;J. Hammond
共 23 条
OVARIAN GROWTH FACTORS
-
批准号:2901793
-
项目类别:
-
资助金额:$6.29万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:6205086
-
项目类别:
-
资助金额:$6.56万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:2763581
-
项目类别:
-
资助金额:$4.04万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN IGFS: ENDOCRINE VS PARACRINE EFFECTS
-
批准号:2673809
-
项目类别:
-
资助金额:$24.9万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:2838741
-
项目类别:
-
资助金额:$30.08万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN IGFS: ENDOCRINE VS PARACRINE EFFECTS
-
批准号:2205595
-
项目类别:
-
资助金额:$24.46万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:2609072
-
项目类别:
-
资助金额:$29.39万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:6125646
-
项目类别:
-
资助金额:$30.78万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:6286336
-
项目类别:
-
资助金额:$34.64万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:6476693
-
项目类别:
-
资助金额:$35.68万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN IGFS: ENDOCRINE VS PARACRINE EFFECTS
-
批准号:2889144
-
项目类别:
-
资助金额:$25.83万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN GROWTH FACTORS
-
批准号:2025205
-
项目类别:
-
资助金额:$30.5万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN IGFS: ENDOCRINE VS PARACRINE EFFECTS
-
批准号:2403459
-
项目类别:
-
资助金额:$23.59万
-
财政年份:1996
-
负责人:JAMES M HAMMOND
-
依托单位:
BIOCHEMICAL ENDOCRINOLOGY STUDY SECTION
-
批准号:3554945
-
项目类别:
-
资助金额:$6.9万
-
财政年份:1989
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN CATECHOLESTROGENS
-
批准号:3325986
-
项目类别:
-
资助金额:$15.71万
-
财政年份:1989
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN CATECHOLESTROGENS
-
批准号:2199376
-
项目类别:
-
资助金额:$17.24万
-
财政年份:1989
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN CATECHOLESTROGENS
-
批准号:3325985
-
项目类别:
-
资助金额:$15.11万
-
财政年份:1989
-
负责人:JAMES M HAMMOND
-
依托单位:
OVARIAN CATECHOLESTROGENS
-
批准号:3325983
-
项目类别:
-
资助金额:$14.85万
-
财政年份:1989
-
负责人:JAMES M HAMMOND
-
依托单位:
BIOCHEMICAL ENDOCRINOLOGY
-
批准号:3554942
-
项目类别:
-
资助金额:$29.3万
-
财政年份:1989
-
负责人:JAMES M HAMMOND
-
依托单位:
BIOCHEMICAL ENDOCRINOLOGY
-
批准号:3554948
-
项目类别:
-
资助金额:$6.74万
-
财政年份:1989
-
负责人:JAMES M HAMMOND
-
依托单位:
海外基金